Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0NO1L
|
|||
| Former ID |
DIB006224
|
|||
| Drug Name |
Pascolizumab
|
|||
| Synonyms |
SB-240683; Interleukin-4 antibody, SmithKline Beecham; Anti-IL-4 antibody (humanized), PDL; Anti-IL-4 antibody (humanized), Protein Design Labs
Click to Show/Hide
|
|||
| Drug Type |
Monoclonal antibody
|
|||
| Indication | Asthma [ICD-11: CA23; ICD-10: J45, J45.8] | Phase 2 | [1], [2], [3] | |
| Company |
Novartis
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7786). | |||
| REF 2 | ClinicalTrials.gov (NCT00024544) Pilot Study in Patients With Symptomatic Steroid-Naive Asthma. U.S. National Institutes of Health. | |||
| REF 3 | ClinicalTrials.gov (NCT01638520) Safety and Efficacy of Blocking IL-4 With Pascolizumab in Patients Receiving Standard Therapy for Pulmonary Tuberculosis | |||
| REF 4 | The potential of biologics for the treatment of asthma. Nat Rev Drug Discov. 2012 Dec;11(12):958-72. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.